The dominant mechanism by which PTEN functions to oppose tumour formation is as a core inhibitory component of the oncogenic PI3K-AKT signalling network, in which it metabolises the primary lipid products of the class 1 phosphoinositide 3-kinases (PI3Ks) [60,61]. Here, PIK3CA is linked to neoplasm.